Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

VLA1701

Vaccine · Immune activation, directed at Enterotoxigenic Escherichia coli labile toxin (LT) · developed by Valneva Austria GmbH

Phase 2 Most advanced trial (none active)

VALN Developer

1 Registered trials

What is VLA1701?

VLA1701 is an oral vaccine against labile toxin-producing enterotoxigenic Escherichia coli (LT-ETEC), a bacterium that causes diarrheal illness. It is studied for the prevention of enterotoxigenic E. coli infection and diarrhea.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine
Targets: Enterotoxigenic Escherichia coli labile toxin (LT) (antigen)
Mechanism: Immune activation, directed at Enterotoxigenic Escherichia coli labile toxin (LT)
Therapy area: Gastroenterology, Infectious disease
Developer: Valneva Austria GmbH (VALN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03576183	Phase 2	Enterotoxigenic Escherichia Coli Infection	Completed	VALN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

DiarrheaEnterotoxigenic Escherichia Coli Infection

More from Valneva Austria GmbH

IC51 FDA approved Japanese encephalitis virus vaccine, inactivated FDA approved 3M-052-AF Phase 1 ChAdOx1 nCoV-19 Vaccine Phase 3 IC41 Phase 2 IC43 Phase 2/3 IC47 Phase 1 IC84 Phase 1 ISS 1018 CpG Oligodeoxynucleotide Phase 1 JE-VAX Phase 3 Pneumococcal 7-Valent Conjugate Vaccine Phase 3 VLA1553 Phase 3

Sources

ClinicalTrials.gov NCT03576183

Updated Oct 11, 2026. Something wrong or missing? Report it on the VALN page.

Follow VALN, the company behind VLA1701

See VALN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VALN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z